In recent years considerable research interest has been directed at studying the biological consequences of tissue hypoxia. As this work progresses it becomes increasingly apparent that tissue hypoxia has complex biological consequences. Much is now known about the natural defences of the body to hypoxia, including heat shock protein synthesis and angiogenesis. These systems are normally under rigid control, but this would seem not so in the rheumatoid joint. This accumulation of knowledge has prompted the belated reawakening of interest in joint hypoxia; it is now clear that an understanding of the physiological and pathological effects of joint hypoxia is of great importance to both clinical and research rheumatology.
The evidence SYNOVIAL FLUID A major advantage in the assessment of joint physiology both in health and disease is the accessibility of synovial fluid from the larger joints. Accordingly, many comparative studies have been performed. In 1970 Lund-Olesen reported the results of a major survey comprising synovial fluid samples from 85 rheumatoid knees.' The mean rheumatoid synovial fluid oxygen tension (Po2) was found to be 27 mmHg, significantly lower than in acute traumatic effusions (mean 63 mmHg), although osteoarthritic knees were often hypoxic (mean 43 mmHg). Treuhaft and McCarty,2 in a similar study of 55 rheumatoid patients, agreed with Lund-Olesen in finding that 27% of rheumatoid knees show profound hypoxia with a Po2 less than 15-2 mmHg. Other workers have independently verified this phenomenon. In addition to a low Po2, many studies have shown alterations in rheumatoid synovial fluid physiology which would be expected in a hypoxic state-namely, a raised carbon dioxide tension (Pco2-up to 150 mmHg), raised lactate (up to 10 mmol/l), lowered glucose, and acidosis (pH as low as .`11 The most notable study summarising these changes is by Falchuk,3 who showed that joints with the lowest Po2 (as low as 9 mmHg) also exhibited large increases in Pco2 and lactate; the same joints showed severe microvascular obliteration in the synovial membrane.
It is important to note that physiological measurements in synovial fluid can vary with the patient's activity. This is evident from a recent study, which showed that movement of an inflamed joint can induce significant further decrease in Po2 from a resting baseline.'2 This observation has particular relevance to the concept of joint 'ischaemia-reperfusion' injury.
SYNOVIAL MORPHOLOGY
The sequence of pathological changes in rheumatoid arthritis is closely associated with alterations in the synovial microvasculature. From the mid-eighteenth century to date there have been many detailed subjective descriptions of synovial morphology in health and disease. Much of the described microvascular derangement in synovitis would seem to be both a consequence and cause of further hypoxia. The hypoxia of multilamination of vascular basement membrane, characteristic of rheumatoid arthritis,'3 is seen in other vascular beds in response to hypoxia. '4 15 It also imposes a barrier to oxygen transport. Arteriovenous shunting has been implicated as a cause of focal pockets of ischaemic synovium. This effect could be achieved in several ways, which have been reported independently. The obliteration of terminal vascular plexi2 16 Acute exacerbation of chronic hypoxia A distinguishing property of the diarthrodial joint is its ability to move. The inflamed joint of a mobile patient is unavoidably subjected to movement. This situation we believe has profound significance in joint pathogenesis through the effects of ischaemia-reperfusion injury.38
The environment for ischaemia and reperfusion in rheumatoid synovitis is created by the unique topography of the component parts of a joint, which predisposes the synovium to pressure induced fluctuations in blood supply. The synovium is the innermost confine of the joint space and its fluid. This movable and compressible stroma is backed by the more rigid confines of the musculature and ligaments. It might be expected, therefore, that increasing the volume of fluid effusion concomitantly with synovial centripetal thickening (cf rheumatoid arthritis) generates a pressurised system. This is indeed the case. We have confirmed that the resting intra-articular pressure in chronically inflamed joints is slightly above atmospheric pressure (+ 5-10 mmHg) compared with that of normal joints which is subatmospheric (-5 mmHg). 39 104 The effects of platelet induced Ca2+ increase are not necessarily limited to endothelium derived relaxing factor release but may also represent a common mechanism for the release of other endothelium derived mediators, such as von Willebrand factor, plasminogen activator, prostacyclin, and endothelin.
Platelet activating factor
Platelet activating factor is the name given to a family of structurally related acetylated phosphoglycerides, or lipid autacoids. It is well known to be a potentially critical mediator in diverse pathological processes. In this respect many ofthe most important physiological actions of platelet activating factor are platelet independent. Platelet activating factor is synthesised by a variety of cell types after appropriate stimulation. 105 An increasing volume of evidence indicates that its synthesis or release can be stimulated in ischaemia.'06'08 Furthermore, it has been suggested that platelet activating factor release accounts for some of the damage seen in ischaemic conditions as treatment with platelet activating factor antagonists affords protection against such damage.109 110 Platelet activating factor has been implicated in many disorders through various aspects of its multiple biological activities. In the ischaemic synovium of rheumatoid arthritis its most important effects are probably as an accessory factor to increased vascular permeability"'l 112 or in the amplification cycle of endothelial cell injury.'05 Hence, platelet activating factor is a potential participant in the still evolving cycle of events which generate persistent synovial inflammation. 
Angiotensin converting enzyme
Endothelial cells contain angiotensin converting enzyme,
